Spots Global Cancer Trial Database for Vinorelbine in Advanced BRAF-like Colon Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Vinorelbine in Advanced BRAF-like Colon Cancer

Official Title: MoTriColor: A Phase II Study of Vinorelbine in Advanced BRAF-like Colon Cancer

Study ID: NCT03482362

Conditions

Colon Cancer

Interventions

Vinorelbine Tartrate

Study Description

Brief Summary: Vecchione et al showed that suppression of RANBP2 results in mitotic defects only in BRAF-like colon cancer (CC) cells, which leads to cell death. Mechanistically, RANBP2 silencing reduces microtubule outgrowth from the kinetochores, thereby inducing spindle perturbations, providing an explanation for the observed mitotic defects. Vinorelbine mimics RANPB2 silencing in BRAF-like and BRAFV600E CC cell lines. These preclinical data represent a strong rationale to also explore the anti-tumor activity of vinorelbine in patients with advanced BRAF-like (both BRAFm and BRAF wild type) CC. Tumors having this gene signature are referred to as "BRAF-like" and have a similar poor prognosis irrespective of the presence of BRAF(V600E) mutation. Since vinorelbine is standard of care in advanced breast and NSCLC, there is ample experience with the dose and schedule as well as with the safety profile and supportive measures required to prevent side-effects.

Detailed Description:

Keywords

vinorelbine

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Antoni van Leeuwenhoek, Amsterdam, Noord-Holland, Netherlands